OncoSec Medical Inc (NASDAQ:ONCS)‘s stock had its “buy” rating restated by Maxim Group in a note issued to investors on Friday, May 12th. They currently have a $5.00 target price on the biotechnology company’s stock. Maxim Group’s price target indicates a potential upside of 358.72% from the stock’s current price.
The analysts wrote, “Oncosec announced a collaboration and supply agreement with Merck (MRK – $64.43 – NR) to evaluate Immunopulse IL-12 + Keytruda in the upcoming P2b study (PISCES) in metastatic melanoma that have progressed on PD-1 therapy.””
Separately, Noble Financial reiterated a “buy” rating on shares of OncoSec Medical in a research note on Friday, May 12th. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $5.67.
Shares of OncoSec Medical (ONCS) opened at 1.09 on Friday. The stock’s market cap is $22.75 million. OncoSec Medical has a one year low of $0.88 and a one year high of $2.08. The firm has a 50-day moving average of $1.09 and a 200-day moving average of $1.26. OncoSec Medical (NASDAQ:ONCS) last released its earnings results on Thursday, June 1st. The biotechnology company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.06. On average, equities research analysts expect that OncoSec Medical will post ($1.04) earnings per share for the current fiscal year.
Shares of OncoSec Medical (ONCS) opened at 1.09 on Friday. The stock’s market cap is $22.75 million. OncoSec Medical has a one year low of $0.88 and a one year high of $2.08. The firm has a 50-day moving average of $1.09 and a 200-day moving average of $1.26. A hedge fund recently raised its stake in OncoSec Medical stock. Vanguard Group Inc. boosted its position in shares of OncoSec Medical Inc (NASDAQ:ONCS) by 34.4% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 564,106 shares of the biotechnology company’s stock after buying an additional 144,325 shares during the period. Vanguard Group Inc. owned approximately 2.70% of OncoSec Medical worth $722,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 8.39% of the company’s stock.
Receive News & Ratings for OncoSec Medical Inc Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for OncoSec Medical Inc and related companies with our FREE daily email newsletter.